News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Chiesi Farmaceutici SpA And SALVAT Sign A Worldwide Development And Licensing Agreement For M3 Muscarinic Receptor Antagonists


1/9/2006 12:30:24 PM

Chiesi Farmaceutici S.p.A. and Laboratorios SALVAT have signed an agreement for the development and licensing of new M3 muscarinic receptor antagonists (anti-M3). Under the agreement Laboratorios SALVAT grant worldwide exclusive rights to develop, register, manufacture, promote and sell anti-M3 products to Chiesi Farmaceutici. Nonetheless, Salvat keeps rights to co-market products in Spain and in Central America.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES